This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Integra LifeSciences to Offer aap's LOQTEQ System in the US
by Zacks Equity Research
Global medical technology major, Integra LifeSciences Holdings Corporation (IART) recently inked an agreement with aap Implantate AG, a Berlin-based trauma product maker.
Quality Systems Professional Service a Drag, Competition Rife
by Zacks Equity Research
On May 23, we issued an updated research report on Irvine, CA-based Quality Systems Inc. (QSII), a leading developer and marketer of healthcare information systems.
Envision (EVHC) Acquires Gwinnett Emergency Specialists
by Zacks Equity Research
Envision Healthcare Corporation (EVHC) announced the acquisition of Gwinnett Emergency Specialists, P.C.
Halyard Health (HYH) Expands CORGRIP System Product Line
by Zacks Equity Research
Halyard Health (HYH), a leading medical technology company, recently announced the expansion of its CORGRIP Nasogastric/Nasointestinal Tube Retention System product line.
Hologic (HOLX) Poised on Balanced Growth Amid Currency Woes
by Zacks Equity Research
On May 23, we issued an updated research report on Bedford, MA-based Hologic Inc. (HOLX).
IDEXX Laboratories (IDXX) Raised to Buy on Solid Prospects
by Zacks Equity Research
On May 22, IDEXX Laboratories, Inc. (IDXX), a leading manufacturer of products and services primarily for the companion animal veterinary, was raised by a notch to a Zacks Rank #2 (Buy).
Bruker Corp (BRKR) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Headquartered in Billerica, MA, Bruker Corporation (BRKR) scaled a new 52-week high of $27.85 on May 22, eventually closing a bit lower at $26.62.
RTI Surgical (RTIX) Jumps: Stock Moves Up 5.2% in Session
by Zacks Equity Research
RTI Surgical, Inc. (RTIX) moved big last session, as its shares rose over 5% on the day.
Quality Systems (QSII) Beats Q4 Earnings, Issues FY18 View
by Zacks Equity Research
Irvine, CA-based Quality Systems Inc. (QSII) reported fourth-quarter fiscal 2017 adjusted earnings of 18 cents per share, exceeding the Zacks Consensus Estimate by a penny. Earnings remained flat on a year-over-year basis.
McKesson (MCK) Beats Earnings Estimate in Q4, Revenues Miss
by Zacks Equity Research
McKesson Corporation (MCK) reported fourth-quarter fiscal 2017 earnings of $3.39 per share, beating the Zacks Consensus Estimate of $3.04.
Halyard Health-Sustainable Solutions Ink License Agreement
by Zacks Equity Research
Halyard Health (HYH) announced a new license and supply agreement with Sustainable Solutions. The license agreement is aimed at converting recycled HALYARD Wrap into an environment friendly product for healthcare facilities.
Mazor Robotics at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Shares of Israel-based developer of robotic technology and products, Mazor Robotics Ltd. (MZOR), rallied to a new 52-week high of $45.64 on May 18.
Exactech (EXAC) Gets FDA Approval for ExactechGPS Application
by Zacks Equity Research
Exactech Inc. (EXAC) recently announced that it has received clearance from the U.S. Food and Drug Administration to market its proprietary ExactechGPS Shoulder Application in US.
Halyard Health Announces New Drainage System, Stock Down
by Zacks Equity Research
Halyard Health (HYH), a leading medical technology company, recently announced the availability of the Halyard Enteral Drainage System, a significant addition to the company's comprehensive portfolio of enteral feeding products.
Teleflex to Introduce Arrow AC3 Optimus at EuroPCR, Paris
by Zacks Equity Research
Teleflex Inc. (TFX) announced plans to introduce Arrow AC3 Optimus Intra-Aortic Balloon Pump at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) in Paris during May 16--19.
Can Inogen (INGN) Stock Continue to Grow Earnings?
by Zacks Equity Research
Inogen, Inc (INGN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Inogen (INGN) reported a stellar first quarter of 2017, beating the Zacks Consensus Estimate for both the counts. The company witnessed solid growth in revenues and adjusted earnings on a year-over-year basis.
Medical Product Q1 Earnings Due on May 9: XRAY, HSIC & More
by Zacks Equity Research
Medical product, an important part of the medical device subcategory within the broader Medical sector, looks promising at the moment.
Cardinal Health (CAH) Q3 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Cardinal Health Inc. (CAH) reported third-quarter fiscal 2017 adjusted earnings of $1.53 per share, which beat the Zacks Consensus Estimate of $1.46 and increased 7% on a year-over-year basis.
Accuray (ARAY) Incurs Loss in Q3, Revenues Miss Estimates
by Zacks Equity Research
Accuray Inc.(ARAY) reported a loss of 6 cents per share in the third quarter of fiscal 2017, comparing unfavorably with the Zacks Consensus Estimate of earnings of a penny.
IDEXX Laboratories (IDXX) Beats Q1 Earnings, Raises View
by Zacks Equity Research
IDEXX Laboratories Inc. (IDXX) recorded first-quarter 2017 earnings per share (EPS) of 77 cents, up 51% (up 53% at constant exchange rate or CER) year over year on a reported basis.
ResMed (RMD) Beats Q3 Earnings, Misses Sales Estimates
by Zacks Equity Research
ResMed Inc. (RMD) announced third-quarter fiscal 2017 adjusted earnings per share (EPS) of 71 cents, up 2.8% from the prior-year quarter level.
Abaxis (ABAX) Beats Q4 Earnings Estimates, Revenues In Line
by Zacks Equity Research
Abaxis, Inc. (ABAX) reported fourth-quarter fiscal 2017 adjusted earnings per share of 33 cents, a penny ahead of the Zacks Consensus Estimate.
athenahealth (ATHN) Misses on Earnings & Revenues in Q1
by Zacks Equity Research
athenahealth Inc. (ATHN) reported adjusted earnings of 10 cents per share in the first quarter of fiscal 2017, which missed the Zacks Consensus Estimate by a penny.
Mead Johnson (MJN) Lags Q1 Earnings, Awaits Merger Closure
by Zacks Equity Research
Mead Johnson Nutrition Company (MJN) reported first-quarter 2017 adjusted earnings per share (EPS) of 80 cents at constant exchange rate or CER, down 8% year over year.